Previous close | 64.23 |
Open | 63.42 |
Bid | 70.90 |
Ask | 73.65 |
Strike | 210.00 |
Expiry date | 2025-12-19 |
Day's range | 62.67 - 64.23 |
Contract range | N/A |
Volume | |
Open interest | N/A |
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.